Atillasoy Ercem 的 Form 4/A 修正申報
修正Kalaris Therapeutics, Inc.（KLRS），2022/10/26 申報
- 申報編號
- 0000899243-22-034264
- 申報時間
- 2022/10/26
- 交易日
- 2022/10/20-10/21
- 申報延遲
- 6 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2022/10/24
這份申報列了 2 筆非衍生性交易。公開市場賣出合計 $1.83 萬。交易後 6 天申報。
這份修正申報取代了 0000899243-22-034054（2022/10/24 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Atillasoy ErcemCIK 0001818802 | 高階主管（見申報備註） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.40 to $8.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
表 I 有 1 筆交易的價格引用這則附註。
備註
This Form 4/A is being filed correct the transaction dates reported in the original Form 4 filed on October 24, 2022. Officer Title: Chief Regulatory and Safety Officer